Analyst Serge Belanger from Needham maintained a Buy rating on Liquidia Technologies and keeping the price target at $36.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger’s rating is based on several promising developments at Liquidia Technologies. The company recently hosted an R&D event that showcased their proprietary technologies aimed at addressing challenges in respiratory and vascular diseases. A key focus was on Yutrepia, which has demonstrated improved tolerability compared to existing treatments, allowing for higher dosing levels that are linked to better patient outcomes. This has broadened the role of inhaled prostacyclin in treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Additionally, Liquidia introduced their L606 program, which is set to begin a pivotal Phase 3 trial. The L606 program involves a liposomal formulation of treprostinil, offering consistent exposure levels with minimal variations, and has shown promising results in early trials. The upcoming trial aims to support regulatory approval, further enhancing the company’s pipeline. These factors, combined with the anticipated growth in Yutrepia’s sales and an impending patent litigation decision, contribute to Belanger’s optimistic Buy rating for the stock.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.